140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

  1. Park, K.
  2. Tan, E.-H.
  3. Zhang, L.
  4. Hirsh, V.
  5. O'Byrne, K.
  6. Boyer, M.
  7. Yang, J.
  8. Mok, T.
  9. Kim, M.
  10. Paz-Ares, L.
Revue:
Journal of Thoracic Oncology

ISSN: 1556-1380,  1556-0864

Année de publication: 2016

Volumen: 11

Número: 4

Pages: S117-S118

Type: Article

DOI: 10.1016/S1556-0864(16)30250-7 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus